👩🏻‍💻 Meet the Makers

“Implementing Digital Twins - Beyond Convention, Towards Future Science”

At LOTTE Biologics, differentiated technology transfer is grounded in scientific rigor. Data-driven process development enables us to reduce risk, predict outcomes, and maximize the probability of success.

So how do our customers’ complex processes become stable, scalable commercial manufacturing?

Meet Junseong Lee, our MSAT USP specialist, who applies data-driven simulation and scientific modeling to design predictable, reliable bioprocesses from the earliest stages of technology transfer.

As part of the MSAT USP team, Junseong works at the core of technology transfer. He analyzes customer processes before transfer begins, identifying hidden risks early, and translating them into optimized, commercial-ready manufacturing strategies.

“For me, technology transfer isn’t about reproducing a protocol.
It’s about understanding it scientifically—using data, simulation, and prediction to make sure it succeeds at scale.”

🔑 Key Focus Areas
• Data-driven insight through CFD and kinetic modeling
• Proactive risk assessment before scale-up begins
• Designing predictable, reproducible processes for stable commercial production

💡 At LOTTE Biologics, MSAT is more than a support function.
It is the scientific bridge that helps our customers move from innovation to reliable commercial manufacturing—with fewer surprises.

Stay tuned as we continue to introduce the makers behind LOTTE Biologics’ science-driven execution.